How Magnesium Absorption Shifts Across Its Forms

Magnesium appears in dietary supplements as multiple chemical compounds—oxide, citrate, glycinate, chloride, threonate, and others—each pairing the magnesium ion with a different carrier molecule. The body absorbs magnesium primarily in the small intestine, but the rate and completeness of that absorption depend on the solubility of the compound, the saturation of intestinal transporters, and the presence of other dietary factors.

The percentage of magnesium that enters circulation from a given dose is called bioavailability, and it shifts substantially across forms. Some compounds dissolve readily in the acidic environment of the stomach, releasing magnesium ions quickly; others remain largely intact until they reach the intestine or pass through unabsorbed. Understanding these differences requires examining the mechanisms that govern ion release, transporter engagement, and paracellular diffusion.

Ion Release, Transporter Binding, and Paracellular Pathways

When a magnesium compound reaches the stomach, gastric acid begins to dissociate the molecule, separating the magnesium cation from its anion. Solubility in aqueous solution determines how much of the compound dissolves: magnesium citrate and chloride dissolve readily, while magnesium oxide has low solubility and releases ions more slowly. The dissolved magnesium then moves into the duodenum and jejunum, where the majority of absorption occurs.

Two primary pathways move magnesium across the intestinal epithelium. The first is active, transporter-mediated absorption through the protein TRPM6 (transient receptor potential melastatin 6) and TRPM7, which are expressed on the apical surface of enterocytes. These channels are selective for magnesium and operate when luminal concentrations are low to moderate. The second pathway is passive paracellular diffusion, in which magnesium ions pass between epithelial cells through tight junctions. This route becomes more significant when luminal magnesium concentration is high, as occurs after a large oral dose.

The organic anion bound to magnesium can influence both pathways. Citrate, aspartate, and glycinate are small organic molecules that remain soluble and may facilitate ion availability in the intestinal lumen. Amino acid chelates—magnesium bound to glycine or other amino acids—are hypothesized to remain intact longer, potentially interacting with peptide transporters in addition to standard magnesium channels, though direct evidence for this mechanism in humans remains limited. In contrast, the oxide anion contributes no organic ligand and offers no secondary transport route.

Once inside the enterocyte, magnesium moves across the basolateral membrane into the bloodstream via a sodium-magnesium exchanger or through vesicular transport. The efficiency of this step is relatively consistent across forms; the primary determinant of overall bioavailability is the initial crossing of the apical membrane and the solubility of the parent compound.

Compounds, Transporters, and Intestinal Structures

Magnesium oxide is the least soluble common form, with a solubility product constant (Ksp) several orders of magnitude lower than citrate or chloride. It provides the highest percentage of elemental magnesium by weight—approximately 60 percent—but a smaller fraction of that magnesium is absorbed. Studies using urinary excretion and serum response as proxies for absorption have consistently shown lower bioavailability for oxide compared to organic salts.

Magnesium citrate dissolves readily in water and gastric fluid, releasing magnesium ions that are available for both transporter-mediated and paracellular absorption. Citrate itself is metabolized in the Krebs cycle and does not accumulate. This form is commonly used in clinical settings when rapid absorption or a laxative effect is desired, since unabsorbed magnesium draws water into the colon.

Magnesium glycinate and other amino acid chelates are marketed on the premise that the amino acid carrier protects the magnesium ion and facilitates uptake. Glycine is a small, neutral amino acid that may be absorbed via peptide transporters, potentially carrying magnesium along. However, the extent to which intact chelates cross the intestinal barrier, rather than dissociating into free magnesium and glycine, remains unclear. Glycinate formulations are often promoted as gentler on the gastrointestinal tract, reflecting lower osmotic load and less unabsorbed magnesium reaching the colon.

Magnesium chloride is highly soluble and dissociates completely in gastric fluid. It delivers a moderate percentage of elemental magnesium—around 12 percent—but the released ions are readily available for absorption. Chloride is a normal electrolyte and poses no metabolic burden.

TRPM6 and TRPM7 are the principal magnesium channels in the intestine. TRPM6 is also expressed in the distal convoluted tubule of the kidney, where it mediates renal magnesium reabsorption. Genetic mutations in TRPM6 cause hypomagnesemia with secondary hypocalcemia, underscoring its essential role. The regulation of these channels by dietary magnesium intake, vitamin D, and intracellular magnesium status modulates absorption efficiency, similar to how calcium absorption shifts with vitamin D status.

Solubility Limits, Laxative Threshold, and Individual Variation

The solubility advantage of organic magnesium salts becomes a disadvantage when the dose exceeds the absorptive capacity of the small intestine. Unabsorbed magnesium is osmotically active and draws water into the intestinal lumen, producing loose stools or diarrhea. The threshold dose varies by individual and by form: magnesium citrate and sulfate are commonly used as laxatives at doses above 300 to 500 milligrams of elemental magnesium, while magnesium oxide, despite lower bioavailability, may be tolerated at higher total doses because less is initially solubilized.

Paracellular absorption is concentration-dependent but not saturable in the same way transporter-mediated uptake is. When luminal magnesium concentration is very high, a larger fraction moves passively between cells, but total absorption as a percentage of the dose declines because the intestine cannot process the entire bolus before it moves distally. This creates a nonlinear dose-response curve: doubling the dose does not double the amount absorbed.

Individual differences in gut transit time, stomach acidity, and baseline magnesium status further complicate predictions. A person with low magnesium stores may upregulate TRPM6 expression, increasing fractional absorption from any form. Conversely, someone with rapid transit or hypochlorhydria may absorb less from poorly soluble forms like oxide. These variables make direct comparisons between forms difficult outside controlled studies using biomarkers such as serum magnesium, urinary excretion, or erythrocyte magnesium content.

The presence of other nutrients also affects absorption. Calcium competes with magnesium for some transport pathways, and high doses of one may reduce uptake of the other, similar to the competitive dynamics seen in how iron absorption shifts between heme and nonheme forms. Phosphate and phytate can bind magnesium in the gut lumen, reducing the free ion concentration available for absorption.

What Labels Disclose About Form and Elemental Content

The Supplement Facts label must state the amount of elemental magnesium per serving, not the weight of the compound. A product listing "500 mg magnesium oxide" must clarify how much of that is actual magnesium—in this case, approximately 300 mg. The form of magnesium must also be disclosed in the ingredient list, typically in parentheses after the nutrient name: "Magnesium (as magnesium citrate)." These requirements are outlined in what a Supplement Facts label must disclose.

The label does not, however, provide information about bioavailability. Two products delivering 200 mg of elemental magnesium—one as oxide, one as glycinate—will have identical Supplement Facts panels, even though the fraction absorbed may differ. Manufacturers may include claims about "high absorption" or "bioavailable form" on the front label or in marketing materials, but these statements are not standardized and do not require comparative testing.

Third-party testing by organizations that verify label accuracy confirms the amount of elemental magnesium and checks for contaminants, but it does not measure absorption or bioavailability in human subjects. Such testing ensures that a product contains what it claims but says nothing about how much of that magnesium will enter circulation after ingestion.

Clinical studies that compare forms typically use urinary magnesium excretion over 24 hours or the area under the serum concentration curve as endpoints. These methods provide relative rankings—citrate and glycinate generally outperform oxide—but absolute absorption percentages vary by study design, population, and analytical method. Published bioavailability figures for magnesium forms range widely, reflecting these methodological differences.

The form of magnesium in a supplement determines how much of the mineral dissolves, how it engages intestinal transporters, and how much reaches the bloodstream. Solubility, transporter saturation, and paracellular diffusion all shift depending on the compound, the dose, and the individual's physiology. Labels disclose the form and the elemental content, but not the fraction that will be absorbed.

Note: This explains how supplements work. This statement has not been evaluated by the Food and Drug Administration. This information is not intended to diagnose, treat, cure, or prevent any disease, and it is not a substitute for advice from a physician, pharmacist, or registered dietitian.